Shanghai RAAS Blood Products Co Ltd Class A
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The… Read more
Shanghai RAAS Blood Products Co Ltd Class A (002252) - Total Assets
Latest total assets as of September 2025: CN¥38.02 Billion CNY
Based on the latest financial reports, Shanghai RAAS Blood Products Co Ltd Class A (002252) holds total assets worth CN¥38.02 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai RAAS Blood Products Co Ltd Class A - Total Assets Trend (2005–2024)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shanghai RAAS Blood Products Co Ltd Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
Shanghai RAAS Blood Products Co Ltd Class A's total assets of CN¥38.02 Billion consist of 27.5% current assets and 72.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.9% |
| Accounts Receivable | CN¥1.81 Billion | 5.4% |
| Inventory | CN¥4.29 Billion | 12.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥485.01 Million | 1.4% |
| Goodwill | CN¥5.07 Billion | 15.1% |
Asset Composition Trend (2005–2024)
This chart illustrates how Shanghai RAAS Blood Products Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai RAAS Blood Products Co Ltd Class A's current assets represent 27.5% of total assets in 2024, a decrease from 73.8% in 2005.
- Cash Position: Cash and equivalents constituted 8.9% of total assets in 2024, up from 6.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 15.1% of total assets.
Shanghai RAAS Blood Products Co Ltd Class A Competitors by Total Assets
Key competitors of Shanghai RAAS Blood Products Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Shanghai RAAS Blood Products Co Ltd Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shanghai RAAS Blood Products Co Ltd Class A generates 0.24x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shanghai RAAS Blood Products Co Ltd Class A generates $6.52 in net profit.
Shanghai RAAS Blood Products Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.37 | 4.21 | 15.18 |
| Quick Ratio | 1.77 | 2.41 | 8.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥6.87 Billion | CN¥ 6.93 Billion | CN¥ 4.68 Billion |
Shanghai RAAS Blood Products Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Shanghai RAAS Blood Products Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.28 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | CN¥33.63 Billion |
| Market Capitalization | $3.76 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai RAAS Blood Products Co Ltd Class A's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shanghai RAAS Blood Products Co Ltd Class A's assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shanghai RAAS Blood Products Co Ltd Class A (2005–2024)
The table below shows the annual total assets of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥33.63 Billion | +5.33% |
| 2023-12-31 | CN¥31.93 Billion | +4.83% |
| 2022-12-31 | CN¥30.46 Billion | +11.83% |
| 2021-12-31 | CN¥27.24 Billion | +6.84% |
| 2020-12-31 | CN¥25.49 Billion | +115.08% |
| 2019-12-31 | CN¥11.85 Billion | +4.09% |
| 2018-12-31 | CN¥11.39 Billion | -21.22% |
| 2017-12-31 | CN¥14.46 Billion | +9.30% |
| 2016-12-31 | CN¥13.23 Billion | +14.45% |
| 2015-12-31 | CN¥11.56 Billion | +23.21% |
| 2014-12-31 | CN¥9.38 Billion | +495.47% |
| 2013-12-31 | CN¥1.58 Billion | +30.36% |
| 2012-12-31 | CN¥1.21 Billion | +19.69% |
| 2011-12-31 | CN¥1.01 Billion | +8.51% |
| 2010-12-31 | CN¥930.33 Million | +12.74% |
| 2009-12-31 | CN¥825.22 Million | -0.72% |
| 2008-12-31 | CN¥831.19 Million | +171.15% |
| 2007-12-31 | CN¥306.54 Million | -5.73% |
| 2006-12-31 | CN¥325.16 Million | -2.54% |
| 2005-12-31 | CN¥333.63 Million | -- |